BioAge Labs Reports Positive Phase 1 BGE-102 Data, Secures $140.7M in Financing, Extends Cash Runway to 2029

summarizeSummary

BioAge Labs announced positive full Phase 1 clinical trial results for its lead drug candidate BGE-102, demonstrating significant reductions in inflammatory biomarkers. The company also secured $140.7 million in net proceeds from recent offerings, extending its cash runway through 2029, and outlined plans for further pipeline advancement.

check_boxKey Events

• Positive Phase 1 Clinical Data for BGE-102

  BioAge Labs reported positive full Phase 1 SAD/MAD clinical trial results for BGE-102, showing an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at both 120 mg (Day 14) and 60 mg (Day 21) once-daily doses. The drug demonstrated consistent reductions across multiple inflammatory biomarkers with a favorable tolerability profile, indicating potential best-in-class efficacy.

• Successful Capital Raise

  The company secured $107.4 million in net proceeds from an underwritten public offering in January 2026, an additional $16.2 million from the underwriters' option exercise in February 2026, and $17.1 million from its at-the-market (ATM) program as of March 31, 2026, totaling $140.7 million in net proceeds. This capital raise involved the issuance of 8,182,050 new shares, representing approximately 21.9% dilution to shares outstanding as of December 31, 2025.

• Extended Cash Runway

  With $384.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, BioAge Labs estimates its existing capital is sufficient to fund operations and capital expenses through 2029. This significantly extends the company's financial runway, providing stability for ongoing development.

• Pipeline Advancement

  Building on the positive Phase 1 data, the company plans to initiate a Phase 2 dose-ranging proof-of-concept trial for BGE-102 in cardiometabolic disease in mid-2026, with data anticipated by year-end. A Phase 1b/2a proof-of-concept trial for BGE-102 in Diabetic Macular Edema (DME) is also planned for mid-2026, with results expected in mid-2027. Additionally, an Investigational New Drug (IND) application for a novel APJ agonist program is targeted by year-end 2026.

auto_awesomeAnalysis

BioAge Labs' latest quarterly report highlights significant progress in its clinical pipeline and a strengthened financial position. The positive full Phase 1 data for BGE-102, demonstrating substantial reductions in hsCRP, is a crucial de-risking event for its lead candidate and supports the planned advancement into Phase 2 trials for cardiometabolic disease and Phase 1b/2a for diabetic macular edema. The successful capital raise of $140.7 million, while dilutive, provides a robust cash balance of $384.9 million, extending the company's operational runway through 2029. This extended runway is a critical factor for a clinical-stage biotech, reducing immediate financing pressures and allowing sustained investment in its pipeline. The ongoing appeal of a previously dismissed securities class action introduces some legal uncertainty but does not overshadow the significant clinical and financial advancements.